Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Biotech firms Gandeeva Therapeutics and Zymeworks have formed a partnership to use cryo-electron microscopy (cryo-EM) to map antibody-antigen interfaces. This collaboration aims to improve the design and optimization of AI-driven antibody drugs by visualizing complex protein structures.
Why it matters
Advancements in structural biology and cryo-EM are accelerating the development of targeted therapies for complex diseases.
Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery.
The content is a standard corporate press release regarding a technical partnership.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in